[The effect on breathing of flunitrazepam and benzoctamine as adjuvants in spinal anesthesia in broncho-pulmonary risk patients].
The influence of intravenous Flunitrazepam (0.4-0.8 mg), Benzoctamine (10-20 mg) and Placebo (NaCl 0.9%) on pO2, pCO2, forced vital capacity, forced expiratory volume and peak flow were investigated in patients with reduced lung function undergoing orthopaedic surgery under spinal anaesthesia. Both drugs depress respiration: Flunitrazepam immediately, Benzoctamine about 15 min after administration. Both drugs reduce lung function in the postoperative period. They should be administered under careful observation of patients' respiration, administration of oxygen and only in special cases where sedation is necessary to reduce psychological stress. The advantage of regional anaesthesia in patients with high risk of postoperative pulmonary failure seems worth retaining compared to general anaesthesia.
D000775:Anesthesia, Spinal; D000873:Anthracenes; D014151:Anti-Anxiety Agents; D002245:Carbon Dioxide / Q000097:blood; D002986:Clinical Trials as Topic; D005445:Flunitrazepam; D006801:Humans; D007866:Leg / Q000601:surgery; D010101:Oxygen Consumption; D010313:Partial Pressure; D010919:Placebos; D012119:Respiration / Q000187:drug effects*; D012129:Respiratory Function Tests
D000873:Anthracenes; D014151:Anti-Anxiety Agents; D010919:Placebos; D002245:Carbon Dioxide; D005445:Flunitrazepam; C100247:benzoctamine
Beeinflussung der Atmung durch Flunitrazepam und Benzoctamin als Adjuvantien zur Spinalanaesthesie bei bronchopulmonalen Risikopatienten.